GSK press releases
Follow
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
